Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 46

1.

A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction.

Afonso A, Schmiedl S, Becker C, Tcherny-Lessenot S, Primatesta P, Plana E, Souverein P, Wang Y, Korevaar JC, Hasford J, Reynolds R, de Groot MC, Schlienger R, Klungel O, Rottenkolber M.

Eur J Clin Pharmacol. 2016 May 24. [Epub ahead of print]

PMID:
27216032
2.

Evaluating different physician's prescribing preference based instrumental variables in two primary care databases: a study of inhaled long-acting beta2-agonist use and the risk of myocardial infarction.

Uddin MJ, Groenwold RH, de Boer A, Afonso AS, Primatesta P, Becker C, Belitser SV, Hoes AW, Roes KC, Klungel OH.

Pharmacoepidemiol Drug Saf. 2016 Mar;25 Suppl 1:132-41. doi: 10.1002/pds.3860.

PMID:
27038359
3.

Seasonal changes in prescribing of long-acting beta-2-agonists-containing drugs.

Rottenkolber M, Voogd E, van Dijk L, Primatesta P, Becker C, de Groot MC, Plana E, Alvarez Y, Durand J, Slattery J, Afonso A, Requena G, Huerta C, Alvarez A, de Abajo F, Tauscher M, Hasford J, Fischer R, Reynolds R, Schmiedl S.

Respir Med. 2015 Jul;109(7):828-37. doi: 10.1016/j.rmed.2015.01.010. Epub 2015 Jan 31.

PMID:
25976384
4.

Time trends of period prevalence rates of patients with inhaled long-acting beta-2-agonists-containing prescriptions: a European comparative database study.

Rottenkolber M, Voogd E, van Dijk L, Primatesta P, Becker C, Schlienger R, de Groot MC, Alvarez Y, Durand J, Slattery J, Afonso A, Requena G, Gil M, Alvarez A, Hesse U, Gerlach R, Hasford J, Fischer R, Klungel OH, Schmiedl S.

PLoS One. 2015 Feb 23;10(2):e0117628. doi: 10.1371/journal.pone.0117628. eCollection 2015.

5.

Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry.

Tilson H, Primatesta P, Kim D, Rauer B, Hawkins PN, Hoffman HM, Kuemmerle-Deschner J, van der Poll T, Walker UA.

Orphanet J Rare Dis. 2013 Sep 10;8:139. doi: 10.1186/1750-1172-8-139.

6.

Sizable variations in circulatory disease mortality by region and country of birth in six European countries.

Rafnsson SB, Bhopal RS, Agyemang C, Fagot-Campagna A, Harding S, Hammar N, Hedlund E, Juel K, Primatesta P, Rosato M, Rey G, Wild SH, Mackenbach JP, Stirbu I, Kunst AE.

Eur J Public Health. 2013 Aug;23(4):594-605. doi: 10.1093/eurpub/ckt023. Epub 2013 Mar 11.

7.

Relationship between inflammatory cytokines and uric acid levels with adverse cardiovascular outcomes in patients with stable coronary heart disease.

Rothenbacher D, Kleiner A, Koenig W, Primatesta P, Breitling LP, Brenner H.

PLoS One. 2012;7(9):e45907. doi: 10.1371/journal.pone.0045907. Epub 2012 Sep 21.

8.

Mortality from circulatory diseases by specific country of birth across six European countries: test of concept.

Bhopal RS, Rafnsson SB, Agyemang C, Fagot-Campagna A, Giampaoli S, Hammar N, Harding S, Hedlund E, Juel K, Mackenbach JP, Primatesta P, Rey G, Rosato M, Wild S, Kunst AE.

Eur J Public Health. 2012 Jun;22(3):353-9. doi: 10.1093/eurpub/ckr062. Epub 2011 May 20.

9.

Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population.

Primatesta P, Plana E, Rothenbacher D.

BMC Musculoskelet Disord. 2011 May 20;12:103. doi: 10.1186/1471-2474-12-103.

10.

Frequency and risk factors of gout flares in a large population-based cohort of incident gout.

Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodríguez LA.

Rheumatology (Oxford). 2011 May;50(5):973-81. doi: 10.1093/rheumatology/keq363. Epub 2011 Jan 12.

11.

Ethnic inequalities in access to and outcomes of healthcare: analysis of the Health Survey for England.

Nazroo JY, Falaschetti E, Pierce M, Primatesta P.

J Epidemiol Community Health. 2009 Dec;63(12):1022-7. doi: 10.1136/jech.2009.089409. Epub 2009 Jul 20.

PMID:
19622520
12.

Cardiovascular medication, physical activity and mortality: cross-sectional population study with ongoing mortality follow-up.

Stamatakis E, Hamer M, Primatesta P.

Heart. 2009 Mar;95(6):448-53. doi: 10.1136/hrt.2008.152041. Epub 2008 Sep 18.

PMID:
18801779
13.

Cardiovascular surveys: manual of operations.

Primatesta P, Allender S, Ciccarelli P, Doring A, Graff-Iversen S, Holub J, Panico S, Trichopoulou A, Verschuren WM; EUROCISS Research Group.

Eur J Cardiovasc Prev Rehabil. 2007 Dec;14 Suppl 3:S43-61. doi: 10.1097/01.hjr.0000277988.18096.3b. Review.

PMID:
18091135
14.

Self-reported never-drinkers in England 1994-2003: characteristics and trends in adults aged 18-54 years.

Pattenden S, Nanchahal K, Primatesta P, Thom B.

Alcohol Alcohol. 2008 Jan-Feb;43(1):91-6. Epub 2007 Oct 12.

15.

Generalised and abdominal obesity and risk of diabetes, hypertension and hypertension-diabetes co-morbidity in England.

Hirani V, Zaninotto P, Primatesta P.

Public Health Nutr. 2008 May;11(5):521-7. Epub 2007 Sep 4.

PMID:
17767799
16.

Domestic physical activity in relationship to multiple CVD risk factors.

Stamatakis E, Hillsdon M, Primatesta P.

Am J Prev Med. 2007 Apr;32(4):320-327.

PMID:
17383563
17.

Response to Tomsak, R. PDE5 inhibitors and permanent visual loss (Int J Impot Res 2005; 17: 547-549).

Watt SJ, Primatesta P, Siegel R.

Int J Impot Res. 2006 Jul-Aug;18(4):411; author reply 412. No abstract available.

PMID:
16819534
18.

Improvement in hypertension management in England: results from the Health Survey for England 2003.

Primatesta P, Poulter NR.

J Hypertens. 2006 Jun;24(6):1187-92.

PMID:
16685220
19.
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk